Navigation Links
FDA Participates in Global Efforts to Protect Consumers and Patients from Unsafe Drugs on the Internet
Date:9/29/2011

SILVER SPRING, Md., Sept. 29, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration and other regulatory and international partners have completed the International Internet Week of Action (IIWA), a cooperative effort to curb online sales and distribution of counterfeit and illegal medical products.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

This year's IIWA, which ran between Sept. 20 and Sept. 27 is called OPERATION PANGEA IV, focused on websites supplying illegal and dangerous medicines. The operation is the largest Internet-based action of its kind in support of the International Medical Products Anti-Counterfeiting Taskforce.

The goal of the IIWA is to protect the public health by increasing the public's awareness about the dangers and risks associated with purchasing medicines and medical devices from websites, to identify the producers and distributors of counterfeit or otherwise illegal pharmaceutical products or medical devices, to target these individuals or businesses with civil or criminal action, and to seize counterfeit and illegal products and remove them from the supply chain.

"The FDA will continue to work closely with our domestic and international law enforcement and regulatory partners to protect consumers from unapproved and potentially harmful products sold over the Internet," said Dara Corrigan, associate commissioner for regulatory affairs.  "We will continue to aggressively pursue those who sell products which may pose a significant risk to consumer health."

The IIWA also provided an excellent opportunity for the FDA to enhance cooperation with international and domestic regulatory and law enforcement partners to effectively target those involved in the manufacture and distribution of illegal medicines.

FDA's Office of Criminal Investigations, in conjunction with the Center for Drug Evaluation and Research, and the Office of Enforcement targeted 997 websites that are engaged in the illegal sale of unapproved and/or misbranded medicines to U.S. consumers.

During OPERATION PANGEA IV, FDA focused its efforts on websites selling unapproved drugs, such as drugs containing human growth hormone (HGH), sildenafil citrate, or isotretinoin. These unapproved drugs can be detrimental to public health.  Although some drugs containing these active ingredients are approved by FDA for use under the supervision of a licensed medical practitioner, the drugs offered for sale on these websites were not FDA approved, and were offered for sale without requiring a valid prescription.

Improper use of HGH can lead to side effects, including an increased risk of cancer, nerve pain, and elevated cholesterol or glucose levels. Sildenafil citrate tablets are used to treat erectile dysfunction and should not be used in some consumers with heart problems.  Isotretinoin capsules, previously marketed as Accutane in the United States, are used to treat severe nodular acne. The drug carries significant potential risks, including severe birth defects if pregnancy occurs while using this medicine.

To minimize potential risks, FDA approved isotretinoin capsules are only available through restricted distribution in the United States, and patients purchasing unapproved products containing this active ingredient are placed at a higher risk because, among other issues, they bypass existing safety controls.

The FDA sent Warning Letters to the operators of the identified websites, all of which appear to be associated with the same individuals and corporate entities located outside of the United States.

As a follow up, the agency sent notices to the Internet Corporation for Assigned Names and Numbers, Registries, Internet Service Providers (ISPs), and Domain Name Registrars (DNRs) informing them that these websites were selling products in violation of U.S. law.

In many cases, conducting illegal activities also violates ISP and DNR policies and agreements, giving the hosting companies the opportunity to terminate the websites and suspend the use of the domain names. Of the 717 websites addressed in the Warning Letters, a total of 578 have been suspended or no longer offer pharmaceuticals for sale.  The FDA is working with its foreign counterparts to address the remaining websites, which continue to offer unapproved or misbranded prescription medicines to U.S. consumers.

The FDA encourages consumers to report suspected criminal activity at www.fda.gov/oci.

The IIWA is a coordinated effort by INTERPOL, the World Customs Organization, the Permanent Forum of International Pharmaceutical crime , the Heads of Medicines Agencies Working Group of Enforcement Officers, as well as national health and law enforcement agencies from 81 participating countries.  

For more information:

  • Buying Medicines over the Internet

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/BuyingMedicinesOvertheInternet/default.htm

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Shelly Burgess, 301-796-4651, shelly.burgess@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MobileMD Participates in NJ-DV HIMSS Conference, Interoperability Demo
2. Sinovac Participates in UBS Greater China Healthcare Corporate Day
3. Ironman Competitor with Diabetes Encourages Others to Live Without Limits; Inspiring Triathlete Participates in Health Fair at The Medicine Stop 5525 South Pulaski Road, Chicago Thursday, August 26, 2010, 1:00 pm - 4:00 pm
4. Winner Medical Participates in CMEF 2010, China International Medical Equipment Fair, in Shenzhen
5. US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium
6. PharmaNet Development Group Management Participates in the 8th Annual Partnerships in Clinical Trials Conference in Rotterdam
7. UPDATE: US Oncology Research Network Participates in Phase III Follow-up Study to BiPars Investigational Cancer Drug BSI-201
8. Reproductive Partners Participates in New IVF Progesterone Delivery System Study
9. Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General
10. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
11. Global Radiation Therapy Equipment Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016  The University of ... announced today that, as part of the development ... of the first hospitals in the U.S. to start ... Muraszko , M.D., U-M,s chair of neurosurgery. ... neurosurgery. --> The BrightMatter technology from ...
(Date:2/8/2016)... CITY, Calif., Feb. 8, 2016  Aoxing Pharmaceutical Company, Inc. (NYSE ... fiscal year 2016, ended December 31, 2015, the Company achieved ... recorded in the same quarter in fiscal 2015. ... in Q2 of fiscal year 2016 was $2,068,635, or $.03 ... or $.01 per share, in the Q2 of fiscal year ...
(Date:2/8/2016)... Feb. 8, 2016 ... of the "Label-Free Detection Market by ... 2020" report to their offering. ... addition of the "Label-Free Detection Market ... to 2020" report to their offering. ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Tingley Rubber ... Canada to provide its range of unique and advantaged protective solutions to ... that will provide bilingual customer service and marketing support. A new distribution center ...
(Date:2/8/2016)... (PRWEB) , ... February 08, ... ... and security executive networking and relationship-marketing firm, announced today that nominations will ... Information Security Executive® (ISE®) West Awards. , Awards include the Information ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from its ... 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels than ... public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and benefits ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is ... this country. The AutismOne 2016 Conference, which is being held May 25-29 at the ... hear elsewhere about helpful interventions and causes of chronic illness in children. , Very ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd ... to his medical and surgical expertise. Technically known as deoxycholic acid or previously ... as a non-surgical alternative for reduction of fat below the chin (aka the ...
Breaking Medicine News(10 mins):